Max Weight Loss12.3%
Studies3
Participants78
StatusAvailable
AOD-9604
Human Growth Hormone Fragment 176-191
AOD-9604 is a modified fragment of human growth hormone (HGH) comprising amino acids 176-191 from the C-terminus. Developed by Metabolic Pharmaceuticals, this peptide specifically targets fat loss without the growth-promoting effects of full HGH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation), making it a targeted approach for body composition improvement and weight management.
Clinical Safety Profile
Reported Side Effects
Mild injection site irritation
Temporary redness at injection site
Rare headache (dose-related)
Occasional fatigue during adaptation
Minimal gastrointestinal effects
Very low incidence of adverse events
Generally well-tolerated profile
Side Effect Management (Clinical Trial Data)
Injection Site Reactions
Occasional
12.8%
Nausea
Infrequent
8.4%
Headaches
Infrequent
6.7%
Fatigue
Infrequent
5.3%
Dizziness
Infrequent
3.8%
Side Effect Management Strategies
Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise
Clinical Safety Metrics
Good
Overall Safety Rating
8.4%
Discontinuation Rate
Research
Approved Status
CONTRAINDICATIONS
• Known hypersensitivity to growth hormone fragments
• Pregnancy and breastfeeding
• Active cancer or tumor growth
• Severe kidney or liver dysfunction
Medical Disclaimer
AOD-9604 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings.